1. Home
  2. Programs
  3. CME/CE
MinuteCE®

When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease

Stroke-Like Symptoms During Treatment: Safety First

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take 1 Minute Challenge
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
  • Overview

    Navigate key clinical decisions surrounding the use of anti-amyloid therapies in Alzheimer’s disease. Through 6 focused episodes, experts examine blood-based biomarker interpretation, patient selection, ARIA risk and monitoring, acute neurologic symptoms, antithrombotic use, and shared decision-making. Gain practical insights into applying diagnostic and safety considerations to support informed, individualized treatment decisions in clinical practice.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.

    The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.

    Faculty:
    Dani Cabral, MD

    Founder and Medical Director, BrainLove
    Assistant Professor, Depts. of Neurology & Psychiatry
    University of Arizona College of Medicine
    Phoenix, AZ

    Advisor/Consultant/Researcher/Speaker Fees: Alpha Cognition, Eli Lilly, Lantheus

    David C. Weisman, MD
    Director, Clinical Trial Center
    Abington Neurological Associates
    Abington, PA

    Advisor/Consultant/Researcher/Speaker Fees: American Stroke Association, Biogen, Eisai, FDA PCNS Advisory Committee, Lantheus, Lilly, Novartis
    Trial support: Acadia, Acumen, Alnylam, Alzheimer's Association, Cerevel, Cognition, Eisai, Lilly, Novartis, Roche, Sage, Sanofi, Serono, Ventus

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has no relevant relationships to disclose.
    • Libby Lurwick has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Use evidence-based criteria and workflows to identify and triage candidates for amyloid-targeting therapies across care settings
    • Implement standardized protocols for safe initiation, ARIA risk mitigation, MRI surveillance, and adverse-event escalation for amyloid-targeting therapies
    • Integrate interprofessional care pathways and closed-loop communication to coordinate dementia evaluation, treatment, and supportive services
    • Conduct structured, literacy- and culture-tailored shared decision-making encounters to communicate options, benefits, risks, and uncertainties with care partner engagement
  • Target Audience

    This activity has been designed to meet the educational needs of neurologists, geriatricians, and psychiatrists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with Alzheimer’s disease.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until September 16, 2027. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for a maximum of 0.50 contact hour(s)/0.05 CEUs of pharmacy continuing education credit.

    The Universal Activity Number (UAN) for this program is JA0006235-0000-26-121-H01-P. This learning activity is knowledge-based. Upon successful completion of the activity, continuing education credit will be electronically submitted to the National Association of Boards of Pharmacy (NABP). Pharmacists with questions may contact NABP Customer Service at custserv@nabp.net.

    This activity has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for a maximum of 0.50 hours of effective education time. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.  

  • Provider(s)/Educational Partner(s)


    Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.

  • Commercial Support

    This activity is supported by an independent educational grant from Eli Lilly and Company.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

    Reproduction Prohibited 
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free